270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy | Zendy

AI Assistant Blog Pricing

270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.